Evidence map›Paper›PMID 39435336›Full record

ArticleEClinicalMedicine2024

Prevalence of HIV in people with potential HIV-indicator conditions in Germany: an analysis of data from statutory health insurances.

Frederik Valbert, Georg M N Behrens, Markus Bickel, Christoph Boesecke, Stefan Esser, Patrik Dröge, Thomas Ruhnke, Amrei Krings, Daniel Schmidt, Uwe Koppe and 4 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Frederik ValbertInstitute for Healthcare Management and Research, University of Duisburg-Essen, Thea-Leymann-Str. 9, Essen, Germany.
Georg M N BehrensDepartment of Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, Hanover, Germany.
Markus BickelInfektiologikum Frankfurt, Stresemannallee 3, Frankfurt, Germany.
Christoph BoeseckeGerman Centre for Infection Research (DZIF), Venusberg-Campus 1, Bonn, Germany.
Stefan EsserDepartment of Dermatology and Venerology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, Essen, Germany.
Patrik DrögeAOK Research Institute (WIdO), Rosenthaler Strasse 31, Berlin, Germany.
Thomas RuhnkeAOK Research Institute (WIdO), Rosenthaler Strasse 31, Berlin, Germany.
Amrei KringsDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Seestrasse 10, Berlin, Germany.
Daniel SchmidtDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Seestrasse 10, Berlin, Germany.
Uwe KoppeDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Seestrasse 10, Berlin, Germany.
Barbara Gunsenheimer-BartmeyerDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Seestrasse 10, Berlin, Germany.
Lea WienholtInstitute for Healthcare Management and Research, University of Duisburg-Essen, Thea-Leymann-Str. 9, Essen, Germany.
Jürgen WasemInstitute for Healthcare Management and Research, University of Duisburg-Essen, Thea-Leymann-Str. 9, Essen, Germany.
Anja NeumannInstitute for Healthcare Management and Research, University of Duisburg-Essen, Thea-Leymann-Str. 9, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In care of people living with human immunodeficiency virus (HIV), early diagnosis of infection is one of the greatest challenges remaining. A promising approach to increase early diagnosis could be optimized HIV testing in persons with indicator conditions (ICs). ICs are conditions which are AIDS-defining in people living with HIV, conditions that may have significant adverse consequences for the individual's clinical management if the presence of HIV infection is not detected, and conditions with an (undiagnosed) HIV prevalence of ≥0.1%. Methods: In this cohort study, anonymous routine healthcare data of German statutory health insurances from 07/01/2016 to 06/30/2021 based on insured persons with an ICD-10-based diagnosis of selected ICs were analyzed. In a primary analysis, two stratifications (gender and age), and four sensitivity analyses HIV prevalence/incidence were calculated for persons with at least one of 26 IC described in international literature. This study is registered in the German Clinical Trials Register (identifier: DRKS0002874). Findings: Routine healthcare data from 513,509 insured persons were selected for analysis. In the primary analysis, only in malignant neoplasm of bronchus and lung a HIV prevalence was observed with a 95%-CI < 0.1%. ICs with particularly high HIV prevalence were pneumocystosis (40.33%), oral hairy leukoplakia (36.71%), and Kaposi's sarcoma (29.86%). When stratified by gender, it was observed that in female patients, the 95%-CI of HIV prevalence fell below 0.1% for seven ICs. No such effect was observed in male patients. Stratified by age, among patients aged 30 to <60 years, the 95%-CI of HIV prevalence were always ≥0.1%, while in the other groups the 95%-CI fell below 0.1% for several ICs. Interpretation: In samples of patients with ICs in Germany, HIV prevalences/incidences were found to be ≥0.1% for all ICs except malignant neoplasm of bronchus and lung. This confirms the classification of these conditions as ICs for the German context and emphasizes the importance of HIV testing in these populations. Funding: This analysis is part of the HIV testing recommendations in guidelines and practice study (German title of the study: "HIV-Testempfehlungen in Leitlinien und Praxis"; acronym: HeLP), which is funded by the German Federal Joint Committee as part of the Innovationsfonds program to further develop the German healthcare system (funding number 01VSF21050).

Indexed as

Acquired immune deficiency syndromeAIDSHIVHuman immunodeficiency virusIndicator conditions

Identifiers

PMID39435336
PMCPMC11492762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.